1. Home
  2. Media
  3. News
  4. Kordel’s from Malaysia launches two new Bioiberica products with Mobilee® and B2cool®

Kordel’s from Malaysia launches two new Bioiberica products with Mobilee® and B2cool®

10 Nov 2016
Healthcare

Bioiberica presents the beneficial effects of Mobilee and B2cool in an international pharmaceutical congress

The most recent products from Kordel’s, a leading firm in the nutraceutics sector in Malaysia, are born out of the combination of Mobilee® and B2cool®, two nutritional ingredients developed by Bioiberica to improve joint health.

Mobilee® is a natural ingredient with a high concentration of hyaluronic acid, as well as hydrolyzed collagen and polysaccharides. The synergic effect of these two natural components has a beneficial impact on joints, improving their mobility and muscle strength. The efficacy of Mobilee® has been proved by more than ten different clinical and scientific studies. Mobilee® has a powerful lubricating effect on joints, by multiplying by ten our body’s natural production of hyaluronic acid.

B2cool® is a native type II collagen which has been proved to have clinical effects on joint pain and osteoarthritis, reducing swelling and joint pain and strengthening knee function. Clinical essays have proved that this is a safe product free of secondary effects, with a single immune-based action mechanism. This is thanks to the preservation of its biologically active structure, which achieves highly efficient results with very small doses. These were some of the aspects that Marta Masides, Bioiberica’s head of medical marketing, explained to the more than 600 pharmacists which attended the presentation of Kordel’s new products in Kuala Lumpur, Malaysia.

According to the data of a survey carried out by the Community Oriented Program for the. Control of Rheumatic Diseases (COPCORD), most Malaysian osteoarthritis patients suffer from knee osteoarthritis. The percentage of persons suffering from joint pain increases significantly with age, affecting 23% of Malaysians aged 55, and 39% of Malaysians older than 65.

An early treatment might contribute to alleviating the symptoms and may also delay the progression of osteoarthritis. As explained by Marta Masides, “there is a large percentage of the youngest population who want to practice sports, but they can’t due to early joint degeneration. Their symptoms are not severe enough to undergo surgery, but painful enough to limit their sporting activity”. Kordel’s new solution not only can reduce pain; it can prevent and delay the progression of osteoarthritis.